Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL-ACT: ACT targets during PCI
NCT03772613Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Feb 2019
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of heparin in coronary artery disease (CAD), ischemic heart disease (IHD), acute coronary syndrome (ACS), sponsored by Mayo Clinic. Started Feb 2019; status: completed.
02
Drugs
heparin
03
Conditions
coronary artery disease (CAD)ischemic heart disease (IHD)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03772613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772613.